AstraZeneca (LON:AZN)‘s stock had its “outperform” rating reissued by equities researchers at Credit Suisse Group in a report issued on Tuesday. They presently have a GBX 5,800 ($80.13) target price on the biopharmaceutical company’s stock. Credit Suisse Group’s target price would suggest a potential upside of 19.40% from the stock’s current price.
Other analysts have also recently issued reports about the company. JPMorgan Chase & Co. restated an “overweight” rating and issued a GBX 5,500 ($75.99) target price on shares of AstraZeneca in a report on Friday, February 2nd. Goldman Sachs set a GBX 3,800 ($52.50) price target on AstraZeneca and gave the stock a “sell” rating in a report on Monday, February 5th. Barclays reiterated a “top pick” rating and set a GBX 6,300 ($87.04) price target on shares of AstraZeneca in a report on Monday, February 5th. Berenberg Bank increased their price target on AstraZeneca from GBX 5,800 ($80.13) to GBX 6,000 ($82.90) and gave the stock a “buy” rating in a report on Thursday, February 8th. Finally, Shore Capital reiterated a “hold” rating on shares of AstraZeneca in a report on Monday, March 12th. Four analysts have rated the stock with a sell rating, six have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. AstraZeneca currently has an average rating of “Hold” and an average price target of GBX 5,222.52 ($72.15).
Shares of AstraZeneca (LON:AZN) opened at GBX 4,857.50 ($67.11) on Tuesday. The stock has a market capitalization of $61,660.00 and a price-to-earnings ratio of 2,891.37. AstraZeneca has a twelve month low of GBX 4,260 ($58.86) and a twelve month high of GBX 5,520 ($76.26).
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.